Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Adamas Pharmaceuticals Inc (ADMS) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/24/2021 8-K Resignation/termination of a director
Docs: "TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ADAMAS PHARMACEUTICALS, INC.",
"AMENDED & RESTATED BYLAWS OF ADAMAS PHARMACEUTICALS, INC."
10/12/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement and Plan of Merger, by and among Supernus, Supernus Reef, Inc. and Adamas Pharmaceuticals, Inc",
"Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening"
08/09/2021 8-K Quarterly results
06/11/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/23/2021 8-K Quarterly results
02/01/2021 8-K Quarterly results
01/13/2021 8-K Quarterly results
12/02/2020 8-K Entry into a Material Definitive Agreement  Interactive Data
11/23/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/05/2020 8-K Quarterly results
Docs: "Adamas Reports Third Quarter 2020 Financial Results"
09/01/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/06/2020 8-K Quarterly results
06/17/2020 8-K Other Events
06/05/2020 8-K Submission of Matters to a Vote of Security Holders
06/04/2020 8-K Other Events
05/07/2020 8-K Quarterly results
02/25/2020 8-K Quarterly results
01/08/2020 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI ® Product Sales and Outlines Key Priorities for 2020 -- Product sales expected to be approximately $16.3 million for fourth quarter 2019 and approximately $54.6 million for full year 2019 -- -- Total prescriptions of approximately 7,160 for fourth quarter 2019 and approximately 25,780 for full year 2019 --"
01/02/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Adamas Reports Third Quarter 2019 Financial Results"
09/13/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
06/05/2019 8-K Submission of Matters to a Vote of Security Holders
05/09/2019 8-K Quarterly results
Docs: "Adamas Reports First Quarter 2019 Financial Results - First quarter net product sales of $11.7 million - GOCOVRI ® total prescriptions grew to approximately 5,820 in Q1 2019 - Phase 3 study of ADS-5102 in walking impairment in patients with multiple sclerosis on course to complete in Q4 2019 EMERYVILLE, Calif., -- Adamas Pharmaceuticals, Inc. , a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today reported financial results for the first quarter ended March 31, 2019, as well as recent corporate developments. “We remain focused on driving the growth of GOCOVRI for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, and completing our Phase 3 study of ADS-5102 for walking impair..."
04/10/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/04/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018"
01/07/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019 -- GOCOVRI preliminary net sales of approximately $13.3 million for the fourth quarter of 2018 and approximately $34 million for the year -- -- Preliminary total prescriptions of approximately 5,700 for the fourth quarter of 2018 and approximately 15,500 for the year --"
11/01/2018 8-K Quarterly results
Docs: "Adamas Reports Third Quarter 2018 Financial Results - GOCOVRI™ extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions - EMERYVILLE, Calif., – Adamas Pharmaceuticals, Inc. , a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today reported financial results and pipeline updates for the third quarter ended September 30, 2018. “We have established a strong foundation and remain focused on increasing the utilization of GOCOVRI in Parkinson’s disease patients with dyskinesia and OFF,” stated Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. “In addition, we’re pleased with the robust enrollment of the Phase 3 study of AD..."
10/04/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/24/2018 8-K Other Events
09/14/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy